Treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 6, 2006, Pages 16-22

  Souery, Daniel ^a   Papakostas, George I ^b   Trivedi, Madhukar H ^c  

^a ERASME HOSPITAL   (Belgium)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PINDOLOL; PSYCHOSTIMULANT AGENT; REBOXETINE; RESERPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DOSE RESPONSE; DRUG CLASSIFICATION; HUMAN; MAJOR DEPRESSION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STAGING; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT REFUSAL; TREATMENT RESPONSE; UNITED STATES; VALIDATION STUDY;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; COMORBIDITY; CONSENSUS; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC ERRORS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; MODELS, THEORETICAL; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 33746040866     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Trivedi MH, Kleiber BA. Using treatment algorithms for the effective management of treatment-resistant depression. J Clin Psychiatry 2001; 62(suppl 18):25-29
2. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, Ltd; 1995
3. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
4. Souery D, Van der Auwera K. The multiple facets of treatment-resistant depression. CNS Spectr 2004;9:803-807
5. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63:577-584
6. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225
7. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
8. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005;25:336-341
9. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):18-25
10. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340
11. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):10-17
12. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):26-31
13. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry 2005;66(suppl 8):5-12
14. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003;53:743-753
15. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):5-9
16. Parker GB, Malhi GS, Crawford JG, et al. Identifying "paradigm failures" contributing to treatment-resistant depression. J Affect Disord 2005;87: 185-191
17. The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products in the treatment of depression. Available at: http://www.emea.eu.int/pofs/human/ewp/051897en.pdf. Accessed Dec 21, 2005
18. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58(suppl 13):23-29
19. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659
20. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 1999;9:83-91
21. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003;64(suppl 1):5-12
22. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 18):4-11
23. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420
24. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull 1990;26: 429-460
25. Shelton RC. Treatment options for refractory depression. J Clin Psychiatry 1999;60(suppl 4):57-61; discussion 62-63
26. Beasley CM Jr, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200
27. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72
28. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:243-261
29. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, I: non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-675
30. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60
31. White K, Wykoff W, Tynes LL, et al. Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatr J Univ Ott 1990;15:156-158
32. Peselow ED, Filippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HCl, B: data from a double-blind crossover study and from a year-long term trial vs imipramine and placebo. Psychopharmacol Bull 1989;25:272-276
33. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16
34. De Clercq M, Mignon A, and the 600A-GAP-BE Study Group. Efficacy of venlafaxine in depressed patients after failure with prior antidepressant treatment. Eur Neuropsychopharmacol 2000;10(suppl 3):241
35. Reynaert-Dupuis C, Zdanowicza N, Leyman S, et al. Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Prim Care Psychiatry 2002;8:63-68
36. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
37. Thase ME, Friedman ES, Rowland RH. Venlafaxine and treatment-resistant depression. Depress Anxiety 2000;12(suppl 1):55-62
38. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 2003;15:17-22
39. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004;65:337-340
40. Zarate CA, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71
41. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
42. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
43. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, II: MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78: 676-683
44. Amsterdam JD, Berwish NJ. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 1989;22:21-25
45. Roose SP, Glassman AH, Walsh BT, et al. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986;143;345-348
46. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219
47. Mendlewicz J, Lecrubier Y. Antidepressant selection: proceedings from a TCA/SSRI Consensus Conference. Acta Psychiatr Scand Suppl 2000; 403:5-8
48. de la Gandara J, Aguera L, Rojo JE, et al. Use of antidepressant combinations: which, when and why? results of a Spanish survey. Acta Psychiatr Scand Suppl 2005;428:32-36
49. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004;65(suppl 16):27-32
50. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005; 66(suppl 8):22-29
51. Erman MK. Therapeutic options in the treatment of insomnia. J Clin Psychiatry 2005;66(suppl 9):18-23
52. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005;62:2481-2490
53. Meoni P, Hackett D, Lader M. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depress Anxiety 2004;19:127-132
54. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 2004;37:93-97
55. What is STAR*D? STAR*D Web Site. Available at: http://www.edc.gsph.pitt.edu/stard/public/. Accessed December 22, 2005
56. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression [Images in Neuroscience]. Am J Psychiatry 2003;160:237